Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firmonertinib plus chemotherapy and SBRT as neoadjuvant therapy for EGFR-mutated stage II–IIIB NSCLC
ChiCTR2500105327Phase 2Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Chest Hospital. Primary endpoint: Major Pathological Response (MPR) Rate. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500105327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105327.